Details for Patent: 7,816,383
✉ Email this page to a colleague
Which drugs does patent 7,816,383 protect, and when does it expire?
Patent 7,816,383 protects ESBRIET and is included in two NDAs.
This patent has fifty-five patent family members in thirty-five countries.
Summary for Patent: 7,816,383
Title: | Methods of administering pirfenidone therapy |
Abstract: | The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. |
Inventor(s): | Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 12/684,879 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,816,383 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,816,383
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE | ⤷ Try a Trial | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE | ⤷ Try a Trial | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE | ⤷ Try a Trial | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE | ⤷ Try a Trial | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,816,383
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 3155 | ⤷ Try a Trial | |||
Austria | E526024 | ⤷ Try a Trial | |||
Australia | 2010212490 | ⤷ Try a Trial | |||
Australia | 2011201462 | ⤷ Try a Trial | |||
Australia | 2013204032 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |